UXN유엑스엔

Quick answers about UXN

What does UXN do?

The company develops and commercializes continuous glucose monitoring systems (CGMS), wearable devices that track blood sugar in real time without finger-prick blood draws, using a proprietary nanoporous platinum sensor technology. Its enzyme-free glucose sensor, marketed under the AGMS brand, is aimed at people with diabetes, especially those on insulin therapy, and is positioned to reduce manufacturing and distribution costs compared with enzyme-based CGMS products. The business targets patients who need continuous blood sugar monitoring and also people who want to understand how diet, exercise and lifestyle affect their glucose levels.

What is the market cap of UXN?

The market capitalisation of UXN was ₩31B at the close on Oct 26, 2026.

Who are the largest shareholders of UXN?

According to the latest official filings, the largest reported holders are SD Biosensor (25.22%, as of Jan 23, 2025); Park Se-jin (15.63%, as of Nov 1, 2024); Choi Byung-cheol (12.30%, as of Aug 20, 2026).

When is the next earnings report from UXN?

Korean companies rarely announce results dates in advance. Based on when UXN filed the same report in past years, its next annual results is expected between Mar 20, 2027 and Mar 23, 2027.